|
Name |
2-Isopropyl-3-methoxycinnamic acid
|
Molecular Formula | C13H16O3 | |
IUPAC Name* |
(E)-3-(3-methoxy-2-propan-2-ylphenyl)prop-2-enoic acid
|
|
SMILES |
CC(C)C1=C(C=CC=C1OC)/C=C/C(=O)O
|
|
InChI |
InChI=1S/C13H16O3/c1-9(2)13-10(7-8-12(14)15)5-4-6-11(13)16-3/h4-9H,1-3H3,(H,14,15)/b8-7+
|
|
InChIKey |
QWXXXRFASGFHKU-BQYQJAHWSA-N
|
|
Synonyms |
2-ISOPROPYL-3-METHOXYCINNAMIC ACID; BSPBio_002665; SPECTRUM100756; SCHEMBL2280935; CHEMBL1451186; (E)-3-(3-methoxy-2-propan-2-ylphenyl)prop-2-enoic acid; CHEBI:166653; CCG-39842; SDCCGMLS-0066405.P001; NCGC00095455-01; NCGC00095455-02; BRD-K11813414-001-02-4; (E)-3-(2-isopropyl-3-methoxy-phenyl)prop-2-enoic acid
|
|
CAS | NA | |
PubChem CID | 5827643 | |
ChEMBL ID | CHEMBL1451186 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 220.26 | ALogp: | 3.0 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 46.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.787 |
Caco-2 Permeability: | -4.556 | MDCK Permeability: | 0.00002460 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.082 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.017 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.321 | Plasma Protein Binding (PPB): | 81.33% |
Volume Distribution (VD): | 0.301 | Fu: | 14.89% |
CYP1A2-inhibitor: | 0.568 | CYP1A2-substrate: | 0.519 |
CYP2C19-inhibitor: | 0.026 | CYP2C19-substrate: | 0.794 |
CYP2C9-inhibitor: | 0.009 | CYP2C9-substrate: | 0.946 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.344 |
CYP3A4-inhibitor: | 0.01 | CYP3A4-substrate: | 0.13 |
Clearance (CL): | 9.383 | Half-life (T1/2): | 0.913 |
hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.111 |
Drug-inuced Liver Injury (DILI): | 0.114 | AMES Toxicity: | 0.027 |
Rat Oral Acute Toxicity: | 0.025 | Maximum Recommended Daily Dose: | 0.262 |
Skin Sensitization: | 0.736 | Carcinogencity: | 0.734 |
Eye Corrosion: | 0.955 | Eye Irritation: | 0.984 |
Respiratory Toxicity: | 0.3 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001101 | 0.473 | D01ZJK | 0.345 | ||||
ENC001547 | 0.434 | D0V9EN | 0.345 | ||||
ENC001030 | 0.415 | D03LGG | 0.316 | ||||
ENC001441 | 0.411 | D0U5CE | 0.316 | ||||
ENC002213 | 0.393 | D0A3HB | 0.305 | ||||
ENC004091 | 0.390 | D0E9CD | 0.304 | ||||
ENC002881 | 0.367 | D09GYT | 0.297 | ||||
ENC000471 | 0.364 | D0E6OC | 0.294 | ||||
ENC004379 | 0.358 | D06REO | 0.291 | ||||
ENC000168 | 0.352 | D01PJR | 0.290 |